Join us on September 13, 2017, as Friends of Cancer Research and Alexandria Real Estate Equities Inc. host this year’s 6th annual A Blueprint for Breakthrough forum! This year's forum will convene multiple stakeholders across academia, government, industry, research and advocacy organizations, and other interested groups to discuss critical aspects for the future development of diagnostic tests.
Advancements in research continue to help identify and inform the use of biomarkers and genomics for therapeutic decision-making. These potential biomarkers and genomic markers are captured in diagnostic tools that have become increasingly important in selecting the most appropriate therapies for patients. This technology has become increasingly advanced, and diagnostic tools are not always binary indicators (e.g., EGFR positive or negative) of whether a drug would be effective or not in a patient. The use of these diagnostics often evolves at a rapid pace and it is necessary to ensure adaptive regulatory processes are in place. This meeting will help elucidate innovative regulatory pathways that can incorporate the rapid technological improvements in precision medicine and baseline considerations for analytical standardization.
The draft agenda for the meeting is included below. Click the button below to register today!
Finalized Meeting Agenda
8:00 AM - Registration and Breakfast
8:30 AM - Welcome Remarks
8:40 AM - Morning Keynote Address
9:00AM - Regulatory Landscape for Precision Medicine
9:15AM - Current State of Precision Medicine Development
9:30 AM – Panel 1 Discussion: Establishing Analytical Standards and Identifying Critical Performance Characteristics
10:15 AM – Q&A
10:45 AM – Break
11:00 AM – Panel 2 Discussion: Streamlining Modifications to Diagnostic Tests
11:45 PM – Q&A
12:15PM - Panel 3 Discussion: Driving Uptake of High Quality Precision Medicine Tools
12:45 PM - Q&A
1:00 PM – Closing Remarks